Carole Mendoza, MBA, MPH

Panelists discuss how defining and tracking meaningful real-world outcomes ensures accountability and value in MASH management.

Panelists discuss how multidisciplinary collaboration is essential for preventing progression and improving outcomes in MASH care.

Panelists discuss how noninvasive risk assessments enable early detection and targeted management of fibrosis in MASH patients.

Panelists discuss how integrating clinical efficacy with cost-effectiveness ensures sustainable adoption of MASH therapies.

Panelists discuss how next-generation metabolic and hepatic agents are broadening treatment options and reshaping the MASH care landscape.

Panelists discuss how GLP-1 therapies show dual metabolic and hepatic benefits, redefining MASH management.

Panelists discuss how recognizing high-risk patients and linking liver care with metabolic management can reduce both disease and economic impact.

Panelists discuss how structured, multidisciplinary screening efforts can catch MASH earlier and prevent progression.

Panelists discuss how metabolic dysfunction drives liver injury, highlighting early recognition of the obesity–MASH connection as key to prevention.